Interaction between a commercially available St. John’s wort product (Movina) and atorvastatin in patients with hypercholesterolemia
- 360 Downloads
The aim of this study was to assess the effect of treatment with a St. John’s wort product (Movina) on cholesterol [total cholesterol, low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol] and triglyceride levels in patients with hypercholesterolemia on treatment with a stable dose of atorvastatin in a controlled, randomised, open, crossover interaction study.
Sixteen patients with hypercholesterolemia treated with a stable dose of atorvastatin (10–40 mg/daily) for at least 3 months were treated with Movina one tablet (containing 300 mg of hypericum perforatum) twice daily and control (a commercially available multivitamin tablet Vitamineral). After a run-in period of 4 weeks, patients were randomised to treatment with either Movina or control for 4 weeks in a crossover design. The atorvastatin dose was kept unchanged during the study period (12 weeks), and assessments of total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides were performed in the morning with the patients in the fasting condition. The difference between control and active treatment in LDL cholesterol after 4 weeks of treatment was the primary endpoint.
All patients completed the study. The St. John’s wort product significantly increased the serum level of LDL cholesterol compared with control (2.66 mmol/l compared with 2.34 mmol/l, p = 0.004). A significant increase in total cholesterol was also observed (5,10 mmol/l compared with 4.78 mmol/l, p = 0.02). No statistically significant change was observed in HDL cholesterol (1.59 mmol/l and 1.56 mmol/l, p = 0.49) or in triglycerides (1.87 mmol/l and 1.94 mmol/l, p = 0.60). No product-related side effects were reported
An interaction was observed between the studied St.-John’s-wort-containing product and atorvastatin. Physicians and patients should be aware of this interaction and if treatment with a St. John’s wort product is considered necessary, then there may be a need for increasing the dose of atorvastatin.
KeywordsSt. John’s wort Hypericum perforatum Atorvastatin Interaction LDL cholesterol
Financial support for this study was in part received from a research grant from the county of Western Sweden (Västra Götalandsregionen).
Conflict of Interest Statement
The authors of this paper have no conflict of interest to declare.
- 6.LUPP. Läkemedelsupplysningen i Västra Sverige (email@example.com)Google Scholar
- 11.Shitara Y, Sugiyama Y (2006) Pharmacokinetic and pharmacodynamic alterations of 3- hydroxy-3- methylglutaryl coenzyme A (HMG- CoA) reductase inhibitors: drug- drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112(1):71–105PubMedCrossRefGoogle Scholar
- 12.Sever PS, Dahlöf B, Poulter NR, Wedel H et.al (2004) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower- than- average cholesterol concentrations, in the Anglo- Scandinavian Cardiac Outcomes Trial. The Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Drugs 64(2):43–60PubMedCrossRefGoogle Scholar
- 15.Major outcomes in moderately hypercholesterolemic hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) (2002) JAMA 288:2998–3007Google Scholar